2-(2-{2-[2-(2-{2-[2-(2-{2-[2-(2-dodecyloxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethanol | 25763-63-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(2-{2-[2-(2-{2-[2-(2-{2-[2-(2-dodecyloxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethanol
• 英文别名: Undecaethylenglykol-mono-n-dodecylether；3,6,9,12,15,18,21,24,27,30,33-Undecaoxapentatetracontan-1-ol；2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol
• CAS: 25763-63-7
• 化学式: C₃₄H₇₀O₁₂
• 分子量: 670.923
• InChiKey: QEZQGPFAVAAYQT-UHFFFAOYSA-N

物化性质

• 沸点：
  673.4±50.0 °C(Predicted)
• 密度：
  1.020±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  46
• 可旋转键数：
  43
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  122
• 氢给体数：
  1
• 氢受体数：
  12

反应信息

• 作为反应物：
  描述：

  2-(2-{2-[2-(2-{2-[2-(2-{2-[2-(2-dodecyloxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethanol 、 碘甲烷 在 sodium hydride 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 0.5h， 以82%的产率得到
  参考文献：
  名称：

  Application of Monodisperse PEGs in Pharmaceutics: Monodisperse Polidocanols

  摘要：

  Polydisperse PEGs are ubiquitously used in pharmaceutical industry and biomedical research. However, the monodispersity in PEGs may play a role in the development of safe and effective PEGylated small molecular drugs. Here, to avoid the polydispersity in polidocanol, the active ingredient in a clinically used drug, a macro cyclic sulfate-based strategy for the efficient and scalable synthesis of monodisperse polidocanols, their sulfates, and their methylated derivatives, was developed. TLC and HPLC analysis indicated a complex mixture in regular polidocanol and high purifies in monodisperse polidocanols and their derivatives. Assay on HUVEC, L929, and HePG2. cells showed-that monodisperse polidocanols have much higher cytotoxicity and safety than that of regular polidocanol. It was found that the monodispersity of PEGs in polidocanols is crucial for achieving the optimal therapeutic results. Therefore, based on this case study, it would be beneficial to optimize PEGylated small molecular drugs with monodisperse PEGs in pharmaceutical research and development.

  DOI：

  10.1021/acs.molpharmaceut.7b00496
• 作为产物：
  描述：

  四聚乙二醇单月桂醚 在 sodium hydride 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 5.0h， 生成 2-(2-{2-[2-(2-{2-[2-(2-{2-[2-(2-dodecyloxy-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethanol
  参考文献：
  名称：

  Application of Monodisperse PEGs in Pharmaceutics: Monodisperse Polidocanols

  摘要：

  Polydisperse PEGs are ubiquitously used in pharmaceutical industry and biomedical research. However, the monodispersity in PEGs may play a role in the development of safe and effective PEGylated small molecular drugs. Here, to avoid the polydispersity in polidocanol, the active ingredient in a clinically used drug, a macro cyclic sulfate-based strategy for the efficient and scalable synthesis of monodisperse polidocanols, their sulfates, and their methylated derivatives, was developed. TLC and HPLC analysis indicated a complex mixture in regular polidocanol and high purifies in monodisperse polidocanols and their derivatives. Assay on HUVEC, L929, and HePG2. cells showed-that monodisperse polidocanols have much higher cytotoxicity and safety than that of regular polidocanol. It was found that the monodispersity of PEGs in polidocanols is crucial for achieving the optimal therapeutic results. Therefore, based on this case study, it would be beneficial to optimize PEGylated small molecular drugs with monodisperse PEGs in pharmaceutical research and development.

  DOI：

  10.1021/acs.molpharmaceut.7b00496

文献信息

• Non-ionic surface-active agents. Part VII. Solubility of benzoic acid in aqueous solutions of some monododecyl polyoxyalkanols
  作者：B. A. Mulley、A. J. Winfield

  DOI：10.1039/j19700001459

  日期：——

  the solubility of benzoic acid in aqueous solutions of polyoxyalkanols of general formula (C12H25·[OCH2·CH2]mOH)(I) where m= 2–12. The surfactants were prepared by methods giving materials of specific hydrophilic chain length and this was confirmed by gas chromatography. Lower members of the series (m= 2–6) had poor solubilising powers since addition of benzoic acid caused the aqueous solution to separate

  进一步研究了苯甲酸在通式为（C 12 H 25 ·[OCH 2 ·CH 2 ] m OH）（I）的聚氧链烷醇的水溶液中的溶解度，其中m = 2–12。通过提供具有特定亲水链长的材料的方法制备表面活性剂，并通过气相色谱法确认。该系列的下半部分（m = 2–6）的溶解能力较差，因为添加苯甲酸会导致水溶液分离成两个液相，这可能是因为系统的较低固溶温度被降至20°以下。上级成员（m= 7–12）更有效，并且在溶解度极限时分离出固体苯甲酸。将结果与用于描述非离子表面活性剂胶束溶液的溶剂性质的两个模型进行比较。结论是，与苯甲酸吸附在胶束内“核与胶囊”界面的分离模型相比，该分离模型更为令人满意。
• [EN] POLIDOCANOL WITH SINGLE MOLECULAR WEIGHT, AND USE THEREOF<br/>[FR] POLIDOCANOL À MASSE MOLÉCULAIRE UNIQUE ET UTILISATION ASSOCIÉE<br/>[ZH] 一种单一分子量的聚多卡醇及其应用
  申请人：[en]JENKEM TECHNOLOGY CO., LTD. (BEIJING);[zh]北京键凯科技股份有限公司

  公开号：WO2023227069A1

  公开（公告）日：2023-11-30

  本发明涉及单一分子量的聚多卡醇在在制备疾病治疗药物中的应用，所述的聚多卡醇可作为硬化剂和/或止血剂用于治疗，所述单一分子量的聚多卡醇由下述制备方法制备：将单一分子量的聚乙二醇与1-卤代十二烷反应，分离、纯化，得到单一分子量的聚多卡醇。本发明的聚多卡醇生产工艺稳定，质量可控，药效良好，毒副作用小。
• Application of Monodisperse PEGs in Pharmaceutics: Monodisperse Polidocanols
  作者：Zeqiong Yu、Shaowei Bo、Huiyuan Wang、Yu Li、Zhigang Yang、Yongzhuo Huang、Zhong-Xing Jiang

  DOI：10.1021/acs.molpharmaceut.7b00496

  日期：2017.10.2

  Polydisperse PEGs are ubiquitously used in pharmaceutical industry and biomedical research. However, the monodispersity in PEGs may play a role in the development of safe and effective PEGylated small molecular drugs. Here, to avoid the polydispersity in polidocanol, the active ingredient in a clinically used drug, a macro cyclic sulfate-based strategy for the efficient and scalable synthesis of monodisperse polidocanols, their sulfates, and their methylated derivatives, was developed. TLC and HPLC analysis indicated a complex mixture in regular polidocanol and high purifies in monodisperse polidocanols and their derivatives. Assay on HUVEC, L929, and HePG2. cells showed-that monodisperse polidocanols have much higher cytotoxicity and safety than that of regular polidocanol. It was found that the monodispersity of PEGs in polidocanols is crucial for achieving the optimal therapeutic results. Therefore, based on this case study, it would be beneficial to optimize PEGylated small molecular drugs with monodisperse PEGs in pharmaceutical research and development.